Skip to main content
Erschienen in: Cardiovascular Drugs and Therapy 1/2011

01.12.2011

Effects of Tolvaptan on Systemic and Renal Hemodynamic Function in Dogs with Congestive Heart Failure

verfasst von: Toshiyuki Onogawa, Yuki Sakamoto, Shigeki Nakamura, Sunao Nakayama, Hiroyuki Fujiki, Yoshitaka Yamamura

Erschienen in: Cardiovascular Drugs and Therapy | Sonderheft 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We investigated the effects of tolvaptan, a vasopressin V2-receptor antagonist, on diuretic response and systemic and renal hemodynamic characteristics in conscious dogs with congestive heart failure (CHF). We also compared these effects with those of furosemide, a loop diuretic.

Methods

CHF was induced by rapid right-ventricular pacing at 260 beats/min for at least 3 weeks, and maintained with a pacing rate of 220–240 beats/min. CHF dogs were orally given tolvaptan (10 mg/kg), furosemide (10 mg/kg) and vehicle in random order during the stable CHF state. Urine excretion, systemic and renal hemodynamic parameters, and plasma hormone levels were measured over 6-hour periods after drug administration.

Results

Tolvaptan induced aquaresis with an increase in free water clearance, resulting in a significant increase in serum sodium concentrations and a decrease in cumulative water balance. Tolvaptan also decreased pulmonary capillary wedge pressure without affecting systemic vascular resistance, glomerular filtration rate or renal blood flow. Tolvaptan tended to increase plasma arginine vasopressin concentrations but did not affect plasma renin activity. In contrast, furosemide induced clear saluresis with increased electrolyte excretion, resulting in decreased pulmonary capillary wedge pressure. However, furosemide also decreased serum potassium concentration and increased plasma arginine vasopressin concentrations and plasma renin activity.

Conclusion

Tolvaptan elicited a potent aquaretic response and reduced the cardiac preload without unfavorable effects on systemic or renal hemodynamics, the renin–angiotensin–aldosterone system, or the sympathetic nervous system in CHF dogs. Thus, tolvaptan may offer a novel approach to remove excess water congestion from patients with CHF.
Literatur
1.
Zurück zum Zitat McInnes G. Diuretics. In: Dukes M, editor. Meyler’s side effects of drugs. Amsterdam: Elsevier Science B.V; 1996. p. 558–82. McInnes G. Diuretics. In: Dukes M, editor. Meyler’s side effects of drugs. Amsterdam: Elsevier Science B.V; 1996. p. 558–82.
2.
Zurück zum Zitat Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–5.PubMed Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311–5.PubMed
3.
Zurück zum Zitat Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.PubMedCrossRef Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–8.PubMedCrossRef
4.
Zurück zum Zitat Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–67.PubMedCrossRef Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–67.PubMedCrossRef
5.
Zurück zum Zitat Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6.PubMed Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6.PubMed
6.
Zurück zum Zitat Anand IS, Kalra GS, Harris P, et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience. 1991;2:273–8.PubMed Anand IS, Kalra GS, Harris P, et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience. 1991;2:273–8.PubMed
7.
Zurück zum Zitat Colucci W. Pathophysiology of heart failure. In: Brounwald E, editor. Heart Disease. Philadelphia: WB Saunders Co.; 1997. p. 394–420. Colucci W. Pathophysiology of heart failure. In: Brounwald E, editor. Heart Disease. Philadelphia: WB Saunders Co.; 1997. p. 394–420.
8.
Zurück zum Zitat Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem. 1999;7:1743–54.PubMedCrossRef Kondo K, Ogawa H, Yamashita H, et al. 7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist. Bioorg Med Chem. 1999;7:1743–54.PubMedCrossRef
9.
Zurück zum Zitat Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.PubMed Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.PubMed
10.
Zurück zum Zitat Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.PubMed Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.PubMed
11.
Zurück zum Zitat Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–6.PubMedCrossRef Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107:2690–6.PubMedCrossRef
12.
Zurück zum Zitat Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.PubMedCrossRef Gheorghiade M, Gattis WA, O’Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004;291:1963–71.PubMedCrossRef
13.
Zurück zum Zitat Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–8.PubMedCrossRef Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273–8.PubMedCrossRef
14.
Zurück zum Zitat Brun C. Thiosulfate determination in kidney function tests; a simple method for the determination of thiosulfate in blood and urine. J Lab Clin Med. 1950;35:152–4.PubMed Brun C. Thiosulfate determination in kidney function tests; a simple method for the determination of thiosulfate in blood and urine. J Lab Clin Med. 1950;35:152–4.PubMed
15.
Zurück zum Zitat Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med. 1963;62:351–6.PubMed Davidson WD, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med. 1963;62:351–6.PubMed
16.
Zurück zum Zitat Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiological studies of heart failure. Circulation. 1986;74:1075–84.PubMedCrossRef Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiological studies of heart failure. Circulation. 1986;74:1075–84.PubMedCrossRef
17.
Zurück zum Zitat Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure. Clin Sci. 1982;62:465–9.PubMed Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure. Clin Sci. 1982;62:465–9.PubMed
18.
Zurück zum Zitat Kearney MT, Fox KA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801–8.PubMedCrossRef Kearney MT, Fox KA, Lee AJ, et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801–8.PubMedCrossRef
19.
Zurück zum Zitat Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol Renal Physiol. 1998;274:F817–33. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol Renal Physiol. 1998;274:F817–33.
20.
Zurück zum Zitat Amorim JB, Malnic G. V1 receptors in luminal action of vasopressin on distal K+ secretion. Am J Physiol Renal Physiol. 2000;278:F809–16.PubMed Amorim JB, Malnic G. V1 receptors in luminal action of vasopressin on distal K+ secretion. Am J Physiol Renal Physiol. 2000;278:F809–16.PubMed
21.
Zurück zum Zitat Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J. 1976;38:167–72.PubMedCrossRef Steiness E, Olesen KH. Cardiac arrhythmias induced by hypokalaemia and potassium loss during maintenance digoxin therapy. Br Heart J. 1976;38:167–72.PubMedCrossRef
22.
Zurück zum Zitat Robertson GL. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med. 1983;101:351–71.PubMed Robertson GL. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med. 1983;101:351–71.PubMed
23.
Zurück zum Zitat Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest. 1973;52:3212–9.PubMedCrossRef Dunn FL, Brennan TJ, Nelson AE, Robertson GL. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest. 1973;52:3212–9.PubMedCrossRef
24.
Zurück zum Zitat Wang BC, Sundet WD, Hakumaki MO, Geer PG, Goetz KL. Cardiac receptor influences on the plasma osmolality-plasma vasopressin relationship. Am J Physiol. 1984;246:H360–8.PubMed Wang BC, Sundet WD, Hakumaki MO, Geer PG, Goetz KL. Cardiac receptor influences on the plasma osmolality-plasma vasopressin relationship. Am J Physiol. 1984;246:H360–8.PubMed
25.
Zurück zum Zitat Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev. 1980;32:81–227.PubMed Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev. 1980;32:81–227.PubMed
26.
Zurück zum Zitat Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83:1A–38.CrossRef Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83:1A–38.CrossRef
27.
Zurück zum Zitat Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540–5.PubMedCrossRef Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:1540–5.PubMedCrossRef
28.
Zurück zum Zitat Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267:H2245–54.PubMed Naitoh M, Suzuki H, Murakami M, et al. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs. Am J Physiol. 1994;267:H2245–54.PubMed
29.
Zurück zum Zitat Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, Johnston CI. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol. 1998;275:H176–82.PubMed Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, Johnston CI. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat. Am J Physiol. 1998;275:H176–82.PubMed
30.
Zurück zum Zitat Takeuchi M, Lee JD, Shimizu H, Ueda T. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats. Int J Cardiol. 2006;108:231–6.PubMedCrossRef Takeuchi M, Lee JD, Shimizu H, Ueda T. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats. Int J Cardiol. 2006;108:231–6.PubMedCrossRef
Metadaten
Titel
Effects of Tolvaptan on Systemic and Renal Hemodynamic Function in Dogs with Congestive Heart Failure
verfasst von
Toshiyuki Onogawa
Yuki Sakamoto
Shigeki Nakamura
Sunao Nakayama
Hiroyuki Fujiki
Yoshitaka Yamamura
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe Sonderheft 1/2011
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6350-4

Weitere Artikel der Sonderheft 1/2011

Cardiovascular Drugs and Therapy 1/2011 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.